Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
NCT01217619
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
erlotinib
Sponsor
Baohui Han